CNSDose

CNSDose specializes in pharmacogenetic testing to enhance medication treatment for mental health disorders, providing tailored insights that support clinicians and patients in optimizing therapeutic strategies. CNSDose, founded in 2015 in Melbourne, Australia, focuses on pharmacogenetic solutions. The company raised USD 1 million in Seed funding on July 13, 2016, to support its operations. Ajeet Singh, the founder, has a history of involvement in innovative health solutions.

CNSDose offers a pharmacogenetic testing service that optimizes medication treatments for individuals with mental health disorders such as depression, anxiety, and ADHD. The service provides an at-home cheek swab test analyzing 19 genes related to drug metabolism and transport, assisting clinicians in medication selection and dosage adjustments. It is specifically designed for the Australian market, particularly for patients with access to Medibank's Mental Health Support, targeting both individual patients and healthcare providers. The test was selected by the University of Melbourne for its clinical relevance in severe mood disorder treatment.

CNSDose generates revenue through direct sales of its pharmacogenetic testing kits, which customers can order online. The process involves customers performing a cheek swab and sending it for analysis, after which a detailed report is provided to facilitate discussions with healthcare providers. The pricing reflects a personalized medicine approach, with potential reimbursements available from health insurance providers like Medibank for eligible members. The company plans to utilize the USD 1 million raised in Seed funding to enhance its product offerings and expand into new markets.

CNSDose aims to develop additional pharmacogenetic tests and is exploring opportunities to enter international markets, particularly targeting regions with growing demand for personalized medicine solutions. The focus remains on optimizing patient outcomes through innovative testing methods.